Rompharm Company

Rompharm Company decreased its stake in Sopharma from c.18% to 9.41%, according to a regulatory filing. Sopharma informed that Rompharm Company has sold almost half of its stake in the Company and currently has 9.41% as of Dec 8th, 2017.

At the same time, Sopharma informed it has increased its bought back shares from c. 4.5% to 6.59% as of Dec. 7th, 2017, according to another regulatory filing. The Company acquired the additional shares at a price of BGN 4.27 per share.

Sopharma has been among the most traded companies on the Bulgarian Stock Exchange with c. 13 million shares or 9.8% of the registered capital changing hands from the start of December 2017. Some of the shares were also acquired by Sopharma’s CEO and key shareholder Ognyan Donev. On Dec. 6th, 2017, Sopharma disclosed Donev acquired 417 567 share at BGN 4.27 per share or c. 0.34% of the Company’s registered capital.

Market reaction to Sopharma shares trading

Active trading with Sopharma shares confirms that transparency in changes of the shareholders‘ structure always adds more trust in the company, commented for seenews.com Dimitar Georgiev, Head of Trading at ELANA Trading. Free float was increased and we will see soaring liquidity with this stock on the Bulgarian Stock Exchange, added Georgiev. He qualified intensified activity with Sopharma shares trading as the core event of the last quarter 2017.

Latest Sopharma earnings

The pharmaceutical company Sopharma increased its sales in November 2017 by double-digit percentages y/y. The Company announced 11% growth of revenues from the domestic market and 12% from export as compared to November 2016. The first 11 months of the year has been marked by 12% revenue growth that had been fueled by the exports. The domestic market contracted by 1% but had been offset by the solid 21% growth of sales abroad, Sopharma said.

Check the latest equity research reports by ELANA Trading